NCT05658146View on ClinicalTrials.gov

A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 6, 2023

Primary Completion Date

July 5, 2023

Study Completion Date

July 5, 2023

Conditions
Healthy Participants
Interventions
DRUG

Mavacamten Capsule 1

Specified dose on specified days

DRUG

Mavacamten Capsule 2

Specified dose on specified days

DRUG

Mavacamten Capsule 3

Specified dose on specified days

Trial Locations (3)

33126

Local Institution - 0002, Miami

65802

Local Institution - 0003, Springfield

92801

Local Institution - 0001, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05658146 - A Study to Assess the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants | Biotech Hunter | Biotech Hunter